In competitive transplant calreticulin‐mutant mouse models, 10 weeks of treatment with INCA033989 prevented thrombocytosis and significantly decreased the numbers of CALR‐mutant stem and progenitor cells, as well as megakaryocytes in the bone marrow, without affecting cellularity of wild‐type mice. Here, CALR is linked to thrombocytosis disease.